Treatments for neurogenetic disorders, impulse control disorders, and wound healing

Abstract

The subject invention provides methods and compositions for the treatment of neurogenetic disorders, particularly DSM-IV impulse control disorders such as intermittent explosive disorder, kleptomania, pyromania, pathologic gambling, trichotillomania, and other impulse control disorders such as compulsive buying and problematic Internet use. In a preferred embodiment, the subject invention provides methods for treating or controlling symptoms associated with ADHD or PWS comprising the administration of therapeutically effective amounts of compositions containing compounds of the formulas I-V. In another embodiment, the subject invention provides for methods of promoting wound healing comprising the administration of a therapeutically effective amount of a composition comprising the compounds of formulas I-V. Compositions may administered to a wound site via a salve, ointment, or as a component of a bandage or bioadhesive applied to the site of injury. The invention also provides therapeutically effective compositions comprising one or more of the compounds of formulas I-V.

Description

CROSS-REFERENCE TO RELATED APPLICATION [0001] This application is a continuation of U.S. patent application Ser. No. 09 / 997,447, filed Nov. 30, 2001,which claims the benefit of U.S. Provisional Application No. 60 / 250,113, filed Nov. 30, 2000, both of which are hereby incorporated by reference herein in their entireties, including any figures, tables, or drawings.BACKGROUND OF THE INVENTION [0002] As many as one-third of the approximate 3,000 known genetic disorders are believed to have important neurological involvement. Individually, most genetic disorders are of low incidence in the general population; however, collectively they represent an enormous burden on affected individuals, their families, and society. Many neurogenetic disorders manifest themselves early in life leading to either a premature death or to lifelong disability with significant attendant psychological and economic hardships. [0003] Examples of these types of disorders include: (1) Hereditary ataxias and relate...

AI Technical Summary

Benefits of technology

[0018] The subject invention provides methods and compositions for the treatment of neurogenetic disorders, particularly DSM-IV impulse control disorders such as intermittent explosive disorder, kleptomania, pyromania, pathologic gambling, trichotillomania, and other impulse control disorders such as compulsive buying and problematic Internet use. In a preferred embodiment, the subject invention provides methods for treating or controlling symptoms associated with ADHD or PWS comprising the administration of therapeutically effective amounts of compositions containing compounds of the formulas I-V. In another embodiment, the subject invention provides for methods of promoting wound healing comprising the administration of a therapeutically effective amount of a composition comprising the compounds of formulas I-V. Compositions are administered to a wound site via a salve, ointment, or as a component of a bandage or bioadhesive applied to the site of injury. The invention also provides therapeutically effective compositions comprising one or more of the compounds of formulas I-V.

Problems solved by technology

Individually, most genetic disorders are of low incidence in the general population; however, collectively they represent an enormous burden on affected individuals, their families, and society.

Many neurogenetic disorders manifest themselves early in life leading to either a premature death or to lifelong disability with significant attendant psychological and economic hardships.

Approximately one-half to two-thirds of children with ADHD will continue to have significant problems in adulthood and experience difficulties which impact employment, familial, and social relationships.

To meet diagnostic criteria, these behaviors must be excessive, long-term, and pervasive.

While there have been no reported efforts to use topiramate for the treatment of impulsivity, there have been a limited number of publications reporting the effects of anti-convulsant treatment on impulsivity (or measures of impulsivity).

Treatment for the physical, behavioral, and psychological problems associated with PWS is complex.

Unfortunately due to cardiovascular consequences, fenfluramine is not now currently available.

There are few studies of anorectic agents in PWS and anecdotal reports have been discouraging in terms of their benefits.

PSP can lead to significant suffering, dysfunction, and disfigurement.

Furthermore, there is often psychiatric comorbidity.

Images